Recent National and Regional Drug Reforms in Sweden
暂无分享,去创建一个
[1] A. Oxman,et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2014, The Cochrane database of systematic reviews.
[2] S. Garattini,et al. Non-inferiority trials are unethical because they disregard patients' interests , 2007, The Lancet.
[3] S. Garattini,et al. How can we regulate medicines better? , 2007, BMJ : British Medical Journal.
[4] A D Oxman,et al. Educational outreach visits: effects on professional practice and health care outcomes. , 2007, The Cochrane database of systematic reviews.
[5] M. Niezen,et al. The Increasingly Complex Fourth Hurdle for Pharmaceuticals , 2007, PharmacoEconomics.
[6] D. Larsson,et al. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. , 2007, Journal of hazardous materials.
[7] Richard Hoey. Experts disagree over NICE's approach for assessing drugs , 2007, The Lancet.
[8] Jane Wells,et al. NICE appraisals should be everybody's business , 2007, BMJ : British Medical Journal.
[9] I. Karlberg,et al. Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. , 2007, Health policy.
[10] J. Catineau,et al. Endpoints in studies on myocardial infarction , 2007, The Lancet.
[11] M. Petzold,et al. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. , 2006, Health policy.
[12] Bengt Jönsson,et al. The costs and benefits of regulations for reimbursement of new drugs. , 2006, Health policy.
[13] Ann Barrett,et al. How much will Herceptin really cost? , 2006, BMJ : British Medical Journal.
[14] B. Wettermark,et al. [Quality indicators for drug prescribing--the situation in Sweden]. , 2006, Lakartidningen.
[15] S. Jansson,et al. The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness. , 2006, Health policy.
[16] C. Furberg,et al. Pharmaceutical policies: effects on rational drug use , 2006 .
[17] Peter Forsberg,et al. Janus computerised prescribing system provides pharmacological knowledge at point of care – design, development and proof of concept , 2006, European Journal of Clinical Pharmacology.
[18] Magnus Wikström,et al. Fixed budgets as a cost containment measure for pharmaceuticals , 2006, The European Journal of Health Economics.
[19] A. Anell,et al. Reimbursement and clinical guidance for pharmaceuticals in Sweden , 2005, The European Journal of Health Economics.
[20] Anders Anell,et al. Swedish healthcare under pressure. , 2005, Health economics.
[21] G. Apolone,et al. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures , 2005, British Journal of Cancer.
[22] B. Wettermark,et al. A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists , 2005, Pharmacoepidemiology and drug safety.
[23] M. Petzold,et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden , 2005, Pharmacoepidemiology and drug safety.
[24] B. Wettermark. Drug utilization 90 % : Using aggregate drug statistics for the quality assessment of prescribing , 2004 .
[25] Anthony J Culyer,et al. National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.
[26] Peter C Smith,et al. Quality incentives: the case of U.K. general practitioners. , 2004, Health affairs.
[27] F. Rocchi,et al. Current National Initiatives About Drug Policies and Cost Control in Europe: The Italy Example , 2004, The Journal of ambulatory care management.
[28] U. Gerdtham,et al. Why did drug spending increase during the 1990s? , 2004, PharmacoEconomics.
[29] B. Wettermark,et al. Drug utilisation 90% profiles—a useful tool for quality assessment of prescribing in primary health care in Stockholm , 2003, Pharmacoepidemiology and drug safety.
[30] C. Pen. The Drug Budget Silo Mentality: The French Case , 2003 .
[31] A. Haycox,et al. Having Your Cake and Eating It , 2012, PharmacoEconomics.
[32] R. Carbajal,et al. Endpoints in studies on myocardial infarction , 2007 .
[33] A. Oxman,et al. Pharmaceutical policies: effects of financial incentives for prescribers. , 2007, The Cochrane database of systematic reviews.
[34] A D Oxman,et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2006, The Cochrane database of systematic reviews.
[35] K. Hassell,et al. Affordability of medicines and patients’ cost-reducing behaviour , 2005, Applied health economics and health policy.
[36] M. Drummond,et al. Reimbursement of pharmaceuticals in the European Union , 2004 .
[37] U. Bergman,et al. Five years' experience of quality assurance and feedback with individual prescribing profiles at a primary healthcare centre in Stockholm, Sweden , 2004 .
[38] C. Le Pen. The drug budget silo mentality: the French case. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] U Bergman,et al. Drug and Therapeutics committees:a Swedish experience. , 2002 .
[40] M. Drummond,et al. Influencing Prescribing in a Primary Care Led NHS , 2002 .
[41] J. Lundkvist. Pricing and reimbursement of drugs in Sweden , 2001, The European Journal of Health Economics.
[42] L. Gustafsson,et al. “Academic drug-detailing”: from project to practice in a Swedish urban area , 1997, European Journal of Clinical Pharmacology.